164,948 results match your criteria antiepileptic drug

A Randomized Controlled Trial of High Rate rTMS Versus rTMS and Amitriptyline in Chronic Migraine.

Pain Physician 2021 Sep;24(6):E733-E741

Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow 226014, India.

Background: The patients with chronic migraine (CM) respond poorly to pharmacological agents including tricyclic antidepressants, beta-blockers, anticonvulsants, calcium channel blockers, flunarizine, and melatonin. The combination of 2 or more pharmacological agents has not shown better efficacy but increased side effects. High rate repetitive transcranial magnetic stimulation (rTMS) has been reported effective in episodic migraine and converts CM to episodic migraine. Read More

View Article and Full-Text PDF
September 2021

Sulthiame monotherapy for epilepsy.

Cochrane Database Syst Rev 2021 Sep 23;9:CD010062. Epub 2021 Sep 23.

Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.

Background: This is an updated version of the original Cochrane Review published in 2014. Epilepsy is a common neurological condition characterised by recurrent seizures. Pharmacological treatment remains the first choice to control epilepsy. Read More

View Article and Full-Text PDF
September 2021

Continuous Electroencephalogram and Antiseizure Medication Use in an International Pediatric Traumatic Brain Injury Population.

Neurocrit Care 2021 Sep 22. Epub 2021 Sep 22.

Medical College of Wisconsin, 9000 W. Wisconsin Ave, Milwaukee, WI, 53226, USA.

Background: Electrographic seizures are frequent and associated with worse outcomes following traumatic brain injury (TBI). Despite this, the use of continuous electroencephalogram (cEEG) remains low. Our study describes cEEG usage and treatment dosing antiseizure medications (ASMs) in an international pediatric TBI population, hypothesizing that children monitored with cEEG have an increased rate of treatment ASMs because of electrographic seizure detection, compared with children who are not monitored with cEEG. Read More

View Article and Full-Text PDF
September 2021

Human Herpes Virus 6 Encephalitis Presenting as Fatal Refractory Status Epilepticus: a Case Report and Systematic Review.

Acta Neurol Taiwan 2021 Mar;30(1):21-26

Department of 1Institute for Neurosciences, St. Luke's Medical Center, Quezon City and Global City, Philippines.

Purpose: Encephalitis secondary to human herpesvirus 6 (HHV-6) infection is frequently encountered in immunocompromised patients; in contrast, HHV-6 encephalitis in immunocompetent patients is rare. There are only 3 reports of status epilepticus due to HHV-6 encephalitis in immunocompetent adults. In the present study, a case of refractory status epilepticus secondary to HHV-6 encephalitis was reported in an immunocompetent female. Read More

View Article and Full-Text PDF

Determinants for Control of Status Epilepticus in Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis.

Acta Neurol Taiwan 2021 Mar;30(1):1-10

Stroke Center and Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.

Background: Treatment guideline for status epilepticus (SE) specifically in patients with anti-N-methyl- D-aspartate receptor (anti-NMDAR) encephalitis is insufficient. This study aimed to clarify the determinants for the control of SE in adult patients with anti-NMDAR encephalitis.

Methods: Medical records of all patients with anti-NMDAR encephalitis hospitalized between Jan. Read More

View Article and Full-Text PDF

Micronutrient characteristic in recurrent seizure in medicinecontrolled epileptic children with normal nutritional status.

Acta Neurol Taiwan 2021 Jun;30(2):54-62

Departement of Child Health Faculty of Medicine, Universitas Airlangga,Indonesia.

Background: Recurrent seizure in epileptic children is correlated with future motoric disorders, behavior problems, and intellectual disabilities. Various factors are thought to modulate the risk of recurrent seizure, including micronutrient status such as calcium, 25-dehydroxycholecalciferol (25-(OH)D), and serum iron presented as hemoglobin level.

Aim: To analyze correlation between micronutrient characteristics of epileptic children and recurrence of seizure. Read More

View Article and Full-Text PDF

Treatment of bipolar disorders in older adults: a review.

Ann Gen Psychiatry 2021 Sep 21;20(1):45. Epub 2021 Sep 21.

Bereich Forschung & Wissenschaft, LWL-Klinik, Marsbruchstr. 179, 44287, Dortmund, Germany.

Background: Old age bipolar disorder has been an orphan of psychiatric research for a long time despite the fact that bipolar disorder (BD)-I and II together may affect 0.5-1.0% of the elderly. Read More

View Article and Full-Text PDF
September 2021

Protective Effect of Aqueous Extract of Lagenaria Siceraria (Molina) Against Maximal Electroshock (MES) -Induced Convulsions in Albino Rats.

Kathmandu Univ Med J (KUMJ) 2017 Apr-Jun;17(58):117-120

Department of Pharmacology, Mamata Medical College, Khammam -507002 Telangana ,India.

Background The Lagenaria siceraria (Molina) belongs to family Cucurbitaceae, commonly known as bottle guard or calabash in English. All the parts of plant like root, fruit, leaves and flower has been evaluated for its various activities like antioxidant, antihelmintic, cognitive enhancer, anticancer, antianxiety, antidepressant, antihyperlipidemic, fibrinolytic cardio protective and hepatoprotective. Even though it is claimed to have antiepileptic action, no documentation is available. Read More

View Article and Full-Text PDF
September 2021

Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations.

Diabetes Res Clin Pract 2021 Sep 18:109063. Epub 2021 Sep 18.

Faculty of Biology, Medicine and Health, University of Manchester and Manchester University Foundation Trust, Manchester, UK.

Diabetic sensorimotor polyneuropathy (DSPN) affects around one third of people with diabetes and accounts for considerable morbidity, increased risk of mortality, reduced quality of life, and increased health care costs resulting particularly from neuropathic pain and foot ulcers. Painful DSPN is encountered in 13-26% of diabetes patients, while up to 50% of patients with DSPN may be asymptomatic. Unfortunately, DSPN still remains inadequately diagnosed and treated. Read More

View Article and Full-Text PDF
September 2021

Lamotrigine for Treating Anger in Veterans With Posttraumatic Stress Disorder.

Clin Neuropharmacol 2021 Sep-Oct 01;44(5):184-185

Phoenix VA Health Care System, Phoenix, AZ.

Abstract: Lamotrigine is an antiepileptic drug that was Food and Drug Administration approved in 2003 for use in the maintenance treatment of bipolar I disorder to delay the time to recurrence of new mood episodes. The mechanism by which lamotrigine achieves its therapeutic effect in the treatment of bipolar disorder is unknown. Here, we report on 2 Veterans with combat-related posttraumatic stress disorder (PTSD) endorsing significant anger, aggression, and agitation, who were treated with selective serotonin reuptake inhibitors, but whose residual symptoms of anger and aggression were ultimately successfully managed with lamotrigine augmentation. Read More

View Article and Full-Text PDF
September 2021

Vigabatrin - new data on indications and safety in paediatric epilepsy.

Neurol Neurochir Pol 2021 Sep 20. Epub 2021 Sep 20.

Department of Child Neurology, Medical University of Warsaw, Żwirki i Wigury 63A, 02-091 Warsaw, Poland.

Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients. However, reports of adverse events of VGB, including VGB-associated visual field loss and brain abnormalities in neuroimaging, have raised concerns about the broader use of VGB and thus significantly limited its application. The goal of this review was to summarise the recent therapeutic guidelines, the use of VGB in focal seizures and new VGB applications as a disease-modifying treatment in TSC patients. Read More

View Article and Full-Text PDF
September 2021

Distribution and risk factors of cleft lip and palate on patients from a sample of Damascus hospitals - A case-control study.

Heliyon 2021 Sep 7;7(9):e07957. Epub 2021 Sep 7.

Faculty of Medicine, Syrian Private University, Damascus, Syria.

Objective: This case-control study was conducted to determine the distribution of cleft lip and/or palate, its association with family history, syndromes and serous otitis media (SOM), and its relation with several risk factors.

Methods: The case group comprised of 133 children born with cleft lip and/or palate, and the control was 133 non-cleft children born full-term. Data was collected including age, gender, origin and risk factors for cleft lip and palate from patients' files, interviewing supervising doctors, and the patient. Read More

View Article and Full-Text PDF
September 2021

A national study of epilepsy-related deaths in Scotland: Trends, mechanisms, and avoidable deaths.

Epilepsia 2021 Sep 19. Epub 2021 Sep 19.

Muir Maxwell Epilepsy Centre, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.

Objective: This study was undertaken to investigate the trends and mechanisms of epilepsy-related deaths in Scotland, highlighting the proportion that were potentially avoidable.

Methods: This was a retrospective observational data-linkage study of administrative data from 2009-2016. We linked nationwide data encompassing mortality records, hospital admissions, outpatient attendance, antiepileptic drug (AED) prescriptions, and regional primary care attendances. Read More

View Article and Full-Text PDF
September 2021

Long-term response and response patterns to antiepileptic drugs in patients with newly diagnosed epilepsy.

Epilepsy Behav 2021 Sep 15;124:108309. Epub 2021 Sep 15.

Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China. Electronic address:

Objective: This study investigated the long-term response and response patterns to antiepileptic drugs (AEDs) in patients with newly diagnosed epilepsy.

Methods: Patients who had been newly diagnosed with epilepsy and had at least 3-year follow-up records were enrolled. Their long-term response and response patterns to AEDs were retrospectively analyzed. Read More

View Article and Full-Text PDF
September 2021

Impact of Psychiatric and Related Somatic Medications on the Duration and Severity of COVID-19: A Retrospective Explorative Multi-center Study from the German Metropolitan Ruhr-area.

Pharmacopsychiatry 2021 Sep 16. Epub 2021 Sep 16.

Department of Psychiatry, Ruhr University Bochum, LWL University Hospital, Bochum, Germany.

Introduction: Several psychiatric and somatic medications are assumed to improve COVID-19-symptoms. These include antidepressants, antipsychotics, and anticonvulsants as well as anticoagulants, statins, and renin-angiotensin-aldosterone-system (RAAS)-inhibitors for somatic comorbid conditions. All these agents may reduce the hyperinflammatory response to SARS/CoV-2 or the related negative cardio-cerebrovascular outcomes. Read More

View Article and Full-Text PDF
September 2021

Efficacy of Brivaracetam in children with epilepsy.

Epilepsy Res 2021 Sep 10;177:106757. Epub 2021 Sep 10.

Hospital Universitario Niño Jesús, Madrid, Neuropediatría, Spain. Electronic address:

Background And Objectives: To determine the efficacy, tolerance, and safety of BRV in children with epilepsy.

Methods: A retrospective study of patients with epilepsy who received treatment with BRV before age 16 years and underwent a minimum follow-up of 3 months.

Method And Results: Sixty-six patients were included in the study. Read More

View Article and Full-Text PDF
September 2021

Treatments for seizures in catamenial (menstrual-related) epilepsy.

Cochrane Database Syst Rev 2021 Sep 16;9:CD013225. Epub 2021 Sep 16.

Department of Health Data Science, University of Liverpool, Liverpool, UK.

Background: This is an updated version of a Cochrane Review previously published in 2019. Catamenial epilepsy describes worsening seizures in relation to the menstrual cycle and may affect around 40% of women with epilepsy. Vulnerable days of the menstrual cycle for seizures are perimenstrually (C1 pattern), at ovulation (C2 pattern), and during the luteal phase (C3 pattern). Read More

View Article and Full-Text PDF
September 2021

[Paroxysmal dysarthria and ataxia - unusual MS manifestation].

Lakartidningen 2021 09 15;118. Epub 2021 Sep 15.

spe-cialistläkare, neurologi, medicin- och geriatrikkliniken, Värnamo sjukhus.

Multiple sclerosis is a common inflammatory demyelinating disease of the central nervous system. Although many patients present permanent symptoms, a number of them suffer of deficits of paroxysmal character. One unusual manifestation of paroxysmal nature is episodes of dysarthria and ataxia known as PDA (paroxysmal dysarthria and ataxia). Read More

View Article and Full-Text PDF
September 2021

Perceived quality of life (QOLIE-31-P), depression (NDDI-E), anxiety (GAD-7), and insomnia in patients with epilepsy attended at a refractory epilepsy unit in real-life clinical practice.

Neurol Sci 2021 Sep 15. Epub 2021 Sep 15.

Epilepsy Unit, Neurology Department, Hospital Universitario de La Princesa & Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.

Objectives: This study aims to evaluate the relationship between psychiatric comorbidity (anxiety and depression), somnolence, and quality of life, using validated scales in patients with epilepsy in real-life clinical practice and clinical and demographic variables.

Methods: A cross-sectional observational study was conducted. Self-administered scales of anxiety disorders (GAD-7), depression (NDDI-E), somnolence (Epworth Sleepiness Scale (ESS)), and quality of life (QOLIE-31-P) in patients with epilepsy treated in the refractory epilepsy unit of a tertiary hospital were employed. Read More

View Article and Full-Text PDF
September 2021

Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Treated Successfully with Oral Cyclosporin: Case report and literature review.

Sultan Qaboos Univ Med J 2021 Aug 29;21(3):491-494. Epub 2021 Aug 29.

Department of Medicine, Rustaq Hospital, Rustaq, Oman.

Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute life-threatening mucocutaneous drug reactions. Several therapies have been used in the treatment of SJS/TEN but none of them have yet been established as the gold standard treatment. Studies have shown that cyclosporine (CsA) can be used off-label in TEN/SJS, which has shown promising therapeutic effectiveness in such diseases. Read More

View Article and Full-Text PDF

Status epilepticus management and mortality risk factors: a retrospective study.

Neurologia (Engl Ed) 2021 Sep 11. Epub 2021 Sep 11.

Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Introduction: Status epilepticus (SE) is a neurological emergency with relatively high mortality rates. In this study, we analysed the management of SE and identified mortality risk factors that may be addressed with educational interventions or modifications to hospital protocols.

Methods: In this retrospective study, we analysed demographic, treatment, and outcome data from 65 patients (mean age, 59 years [range, 44. Read More

View Article and Full-Text PDF
September 2021

Pharmacokinetic variability of eslicarbazepine in real clinical practice.

Epilepsy Behav 2021 Sep 11;124:108284. Epub 2021 Sep 11.

Department of Neurology, Instituto de investigacion Sanitaria Princesa, La Princesa University Hospital, Madrid, Spain.

Introduction: Eslicarbazepine acetate (ESL) is a sodium channel blocker indicated for partial-onset seizures with or without secondary generalization, at a single daily dose. There are very few publications on the levels of ESL metabolites in real clinical practice.

Objective: To describe the serum levels of licarbazepine (main metabolite of ESL) in patients with refractory epilepsy in real clinical practice. Read More

View Article and Full-Text PDF
September 2021

Personalized treatment with retigabine for pharmacoresistant epilepsy arising from a pathogenic variant in the KCNQ2 selectivity filter.

Epileptic Disord 2021 Sep 14. Epub 2021 Sep 14.

Physiology Department, The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Mutations in the KCNQ2 gene, encoding the voltage-gated potassium channel, Kv7.2, cause neonatal epilepsies. The potassium channel opener, retigabine, may improve epilepsy control in cases with loss-of-function mutations, but exacerbate seizures in cases with gain-of-function mutations. Read More

View Article and Full-Text PDF
September 2021

Phenobarbital versus valproate for generalized convulsive status epilepticus in adults (2): A multicenter prospective randomized controlled trial in China (China 2-P vs. V).

Epilepsy Res 2021 Sep 9;177:106755. Epub 2021 Sep 9.

Department of Neurology, Zhongshan Hospital, Xiamen University, Xiamen, 200032, China.

Objective: A multicenter study of phenobarbital versus valproate (i.e., the China 2-P vs. Read More

View Article and Full-Text PDF
September 2021

Researching on the compliance of epilepsy patients of the Phenobarbital Epilepsy Management Project in a rural area of China: A retrospective study.

Medicine (Baltimore) 2021 Sep;100(36):e27172

Department of Social Medicine and Health Management, School of Medicine, Hunan Normal University, Changsha, Hunan, China.

Abstract: The aim of this study was to explore the compliance of epilepsy patients in the Phenobarbital Epilepsy Management Project in a rural area of China and its influencing factors, so as to provide the basis for further strategies.A retrospective study researching on the compliance of epilepsy patients in the Phenobarbital Epilepsy Management Project of Rural China was conducted. The Nan County, Hunan Province as a typical rural China was selected as the study site. Read More

View Article and Full-Text PDF
September 2021

Investigating Neuroprotective Potential of Berberine, Levetiracetam and Their Combination in The Management of Alzheimer's Disease Utilizing Drug Repurposing Strategy.

Curr Rev Clin Exp Pharmacol 2021 Sep 9. Epub 2021 Sep 9.

Institute of Pharmacy, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida- -201306, Uttar Pradesh. India.

Aim: The aim of the present work was to evaluate the neuroprotective potential of berberine, levetiracetam and their combination in lead acetate induced neurotoxicity by applying a drug repositioning approach.

Background: Alzheimer's disease (AD) is a neurodegenerative disease characterized by impairment of memory, disturbances in reasoning, planning, language and perception. Currently, there are only four drugs approved by US-FDA for AD; therefore, there is an extensive need for new drug development. Read More

View Article and Full-Text PDF
September 2021

Drug treatment of epilepsy: From serendipitous discovery to evolutionary mechanisms.

Curr Med Chem 2021 Sep 10. Epub 2021 Sep 10.

Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou. China.

Epilepsy is a chronic brain disorder caused by abnormal firing of neurons. Up to now, using antiepileptic drugs is the main method of epilepsy treatment. The development of antiepileptic drugs lasted for centuries. Read More

View Article and Full-Text PDF
September 2021


Georgian Med News 2021 Jul-Aug(316-317):61-63

David Tvildiani Medical University; Javrishvili Eye Clinic «Oftalmij», Tbilisi, Georgia.

Goal - assessment of Diacarb (Acetazolamide) role in prevention of cataract phacoemulsification complications. Study includes 400 patients, 300 of which comprise the control group while 100 patients were administered one dose of Diacarb orally, one day before the surgery. The patients were observed in the course of surgery, as well as in the post-surgery period. Read More

View Article and Full-Text PDF
September 2021

Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice.

Epilepsia 2021 Sep 12. Epub 2021 Sep 12.

Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Objective: Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) most often caused by de novo pathogenic variants in SCN1A. Individuals with Dravet syndrome rarely achieve seizure control and have significantly elevated risk for sudden unexplained death in epilepsy (SUDEP). Heterozygous deletion of Scn1a in mice (Scn1a ) recapitulates several core phenotypes, including temperature-dependent and spontaneous seizures, SUDEP, and behavioral abnormalities. Read More

View Article and Full-Text PDF
September 2021

Clinical Characteristics, Treatment Effectiveness, and Predictors of Response to Pharmacotherapeutic Interventions Among Patients with Herpetic-Related Neuralgia: A Retrospective Analysis.

Pain Ther 2021 Sep 12. Epub 2021 Sep 12.

Shenzhen Municipal Key Laboratory for Pain Medicine, Department of Pain Medicine, Shenzhen Nanshan People's Hospital, The 6th Affiliated Hospital of Shenzhen University Health Science Center, National Key Clinical Pain Medicine of China, Shenzhen, 518060, China.

Background: The treatment for herpetic-related neuralgia focuses on symptom control by use of antiviral drugs, anticonvulsants, and tricyclic antidepressants. We aimed to explore the clinical characteristics associated with medication responsiveness, and to build a classifier for identification of patients who have risk of inadequate pain management.

Methods: We recruited herpetic-related neuralgia patients during a 3-year period. Read More

View Article and Full-Text PDF
September 2021